Chronic Myelogenous Leukemia - Treatment Options, Symptoms, Causes & Diagnosis from MedifocusHealth

Chronic Myelogenous Leukemia > What Your Doctor is Reading About Chronic Myelogenous Leukemia > Drug Therapy

Drug Therapy

1. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.

Author: Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF;
Institution: Department of Hematology, Second Affiliated Hospital, Hangzhou, Zhejiang Province 310009,China. zrxyk10@zju.edu.cn
Journal: Leuk Res. 2006 Jan;30(1):17-23. Epub 2005 Jul 14.
Abstract URL: Click here to view abstract

2. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.

Author: Jabbour E; Kantarjian H; O'Brien S; Rios MB; Abruzzo L; Verstovsek S; Garcia-Manero G; Cortes J;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Blood. 2006 Jan 15;107(2):480-2. Epub 2005 Sep 29.
Abstract URL: Click here to view abstract

3. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Author: Rea D; Legros L; Raffoux E; Thomas X; Turlure P; Maury S; Dupriez B; Pigneux A; Choufi B; Reman O; Stephane D; Royer B; Vigier M; Ojeda-Uribe M; Recher C; Dombret H; Huguet F; Rousselot P;
Institution: Service d'Hematologie Clinique, Hopital Saint-Louis, Paris, France.
Journal: Leukemia. 2006 Mar;20(3):400-3.
Abstract URL: Click here to view abstract

4. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Author: Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD;
Institution: Dana Farber Cancer Institute, Mayer 540, 44 Binney Street, Boston, MA 02115, USA.
Journal: Nat Rev Cancer. 2007 May;7(5):345-56.
Abstract URL: Click here to view abstract

5. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

Author: Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M;
Institution: Department of Hematology/Oncology L. and A. Seragnoli S. Orsola Malpighi Hospital, University of Bologna, Bologna, Italy. francesca.palandri@libero.it
Journal: J Clin Oncol. 2008 Jan 1;26(1):106-11.
Abstract URL: Click here to view abstract

6. Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group.

Author: Sugita J; Tanaka J; Kurosawa M; Fukuhara T; Hashino S; Torimoto E; Koizumi K; Masauji N; Nishimura S; Koda K; Imamura M; Kasai M;
Institution: Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Journal: Eur J Haematol. 2008 Feb;80(2):160-3. Epub 2007 Nov 17.
Abstract URL: Click here to view abstract

7. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Author: Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D;
Institution: Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA.
Journal: J Clin Invest. 2007 Sep;117(9):2408-21.
Abstract URL: Click here to view abstract

8. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

Author: Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H;
Institution: Department of Leukemia, Unit 428, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Journal: IDrugs. 2007 Jul;10(7):468-79.
Abstract URL: Click here to view abstract

9. Dasatinib.

Author: Shah NP;
Institution: Division of Hematology/Oncology, UCSF School of Medicine, San Francisco, California 94143, USA. nshah@medicine.ucsf.edu
Journal: Drugs Today (Barc). 2007 Jan;43(1):5-12.
Abstract URL: Click here to view abstract

10. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.

Author: Quintas-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J;
Institution: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center. Houston, TX 77030, USA.
Journal: Leuk Lymphoma. 2007 Feb;48(2):283-9.
Abstract URL: Click here to view abstract

11. The effects of imatinib on pregnancy outcome.

Author: Pye SM; Cortes J; Ault P; Hatfield A; Kantarjian H; Pilot R; Rosti G; Apperley JF;
Institution: Department of Haematology, Division of Investigative Science, Imperial College, London, United Kingdom. s.pye@imperial.ac.uk
Journal: Blood. 2008 Jun 15;111(12):5505-8. Epub 2008 Mar 5.
Abstract URL: Click here to view abstract

12. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Author: Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Muller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM;
Institution: III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Mannheim, Germany. hochhaus@uni-hd.de
Journal: Leukemia. 2008 Jun;22(6):1200-6. Epub 2008 Apr 10.
Abstract URL: Click here to view abstract

13. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Author: Roy L; Guilhot J; Krahnke T; Guerci-Bresler A; Druker BJ; Larson RA; O'Brien S; So C; Massimini G; Guilhot F;
Institution: Department of Oncology-Hematology and Cell Therapy, EA 3805, CHU La Miletrie, 2 Rue de la Miletrie, 86021 POITIERS CEDEX, France.
Journal: Blood. 2006 Sep 1;108(5):1478-84. Epub 2006 Apr 20.
Abstract URL: Click here to view abstract

14. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Author: Jabbour E; Kantarjian H; Jones D; Talpaz M; Bekele N; O'Brien S; Zhou X; Luthra R; Garcia-Manero G; Giles F; Rios MB; Verstovsek S; Cortes J;
Institution: Department of Leukemia, The University of Texas, UT MD Anderson Cancer Center, Houston, TX 77030, USA.
Journal: Leukemia. 2006 Oct;20(10):1767-73. Epub 2006 Jul 20.
Abstract URL: Click here to view abstract

15. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.

Author: Breccia, M; Carmosino, I; Russo, E; Morano, S G; Latagliata, R; Alimena, G;
Institution: Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it
Journal: Eur J Haematol 2005 Feb;74(2):121-3.
Abstract URL: Click here to view abstract

16. Imatinib (Gleevec)-induced hepatotoxicity.

Author: Ayoub, Walid S; Geller, Stephen A; Tran, Tram; Martin, Paul; Vierling, John M; Poordad, F Fred;
Institution: Center for Liver and Kidney Diseases and Transplantation, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Journal: J Clin Gastroenterol 2005 Jan;39(1):75-7.
Abstract URL: Click here to view abstract